RecruitingNCT04561518

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Sponsor

Alnylam Pharmaceuticals

Enrollment

1,500 participants

Start Date

Nov 23, 2020

Study Type

OBSERVATIONAL

Conditions

Transthyretin-Mediated Amyloidosis ATTR Amyloidosis

Summary

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Eligibility

Plain Language Summary

Simplified for easier understanding

The ConTTRibute Registry is a global observational study collecting data on patients with ATTR amyloidosis — a disease caused by abnormal deposits of a protein called transthyretin (TTR) in organs and tissues, particularly the heart and nerves. Some people have hereditary forms of ATTR amyloidosis due to a gene mutation, while others develop a wild-type form with age. New treatments are becoming available, and this registry tracks how well they work in the real world. The registry is open to people of any age and sex who have been diagnosed with ATTR amyloidosis or who carry a known disease-causing TTR gene variant (even before symptoms develop). In Germany, patients must be receiving an approved treatment as directed by its label. You may be eligible if: - You have been diagnosed with ATTR amyloidosis (any type), OR - You carry a documented disease-causing TTR gene variant (pre-symptomatic) - (Germany only) You are being treated per the approved label for an ATTR amyloidosis therapy You may NOT be eligible if: - You are currently enrolled in a clinical trial testing an investigational agent for ATTR amyloidosis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(40)

Clinical Trial Site

La Jolla, California, United States

Clinical Trial Site

Los Angeles, California, United States

Clinical Trial Site

Jacksonville, Florida, United States

Clinical Trial Site

Iowa City, Iowa, United States

Clinical Trial Site

Kansas City, Kansas, United States

Clinical Trial Site

Baltimore, Maryland, United States

Clinical Trial Site

Boston, Massachusetts, United States

Clinical Trial Site

New York, New York, United States

Clinical Trial Site

Durham, North Carolina, United States

Clinical Trial Site

Columbus, Ohio, United States

Clinical Trial Site

Philadelphia, Pennsylvania, United States

Clinical Trial Site

Austin, Texas, United States

Clinical Trial Site

Houston, Texas, United States

Clinical Trial Site

Salvador, Brazil

Clinical Trial Site

São Paulo, Brazil

Clinical Trial Site

Sofia, Bulgaria

Clinical Trial Site

Aarhus, Denmark

Clinical Trial Site

Copenhagen, Denmark

Clinical Trial Site

Bordeaux, France

Clinical Trial Site

Bron, France

Clinical Trial Site

Créteil, France

Clinical Trial Site

Le Kremlin-Bicêtre, France

Clinical Trial Site

Marseille, France

Clinical Trial Site

Berlin, Germany

Clinical Trial Site

Giessen, Germany

Clinical Trial Site

Hanover, Germany

Clinical Trial Site

Jerusalem, Israel

Clinical Trial Site

Ramat Gan, Israel

Clinical Trial Site

Milan, Italy

Clinical Trial Site

Naples, Italy

Clinical Trial Site

Palermo, Italy

Clinical Trial Site

Roma, Italy

Clinical Trial Site

Groningen, Netherlands

Clinical Trial Site

Lisbon, Portugal

Clinical Trial Site

Porto, Portugal

Clinical Trial Site

Barcelona, Spain

Clinical Trial Site

Madrid, Spain

Clinical Trial Site

Palma, Spain

Clinical Trial Site

New Taipei City, Taiwan

Clinical Trial Site

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04561518

Related Trials

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT0635593426 locations

The Italian Transthyretin Amyloidosis Web-Network

NCT0544492030 locations

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

NCT0518408814 locations

Orthopaedic Specimen Pathology and Early Diagnosis of ATTR Cardiopathy (ATTR-ORTHO)

NCT063678421 location